Where to start: How to gain a foothold in the China biopharmaceutical market
The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as a global competitor in new drug development and commercialization. China remains the second largest global economy, with USD 5.3 billion+ in VC investment in the life sciences sector in 2016. There are more market entry opportunities than ever before.
ChinaBio® Group, a leading consulting and advisory partner with significant experience in China’s life science industry, has put together an insider’s list of the Top 100* pharmaceutical companies in China to make it easier for life science BD teams to scout and pursue successful cross-partnerships with China-based companies.
Download the “Top 100 pharmaceutical companies in China” list now.
To meet and partner with over 900 global executives from pharma, biotech, finance and cross-border partners, register to attend ChinaBio® Partnering Forum taking place in Zhuhai, China, May 31–June 1, 2017.
